Skip to content

    Lupin

    LUPIN
    Healthcare·7 Nov 2025
    Management Summary

    Lupin delivered a record Q2 FY26, with revenues exceeding INR 7,000 crores and EBITDA over INR 2,100 crores, driven by strong performance across all key markets, particularly the US. Significant margin expansion to 31.3% was achieved through a favorable product mix and operational efficiencies. The company is strategically investing in complex products, biosimilars, and specialty platforms, while also focusing on regulatory compliance and ESG initiatives, though it anticipates some margin tempering in H2 due to increased R&D and lower PLI income.

    Highlights

    7
    • Total revenue from operations exceeded INR 7,000 crores and EBITDA surpassed INR 2,100 crores for the first time in company history.

    • EBITDA margin expanded by 750 basis points YoY and 470 basis points QoQ, reaching 31.3%.

    • Q2 FY26 marks the 13th consecutive quarter of YoY growth, demonstrating business model strength.

    • US business recorded sales of USD 315 million, a growth of 41% YoY and 11.5% QoQ, one of its highest to date.

    • Gross margins improved to 73.3% in Q2 FY26, up from 69.3% in Q2 FY25 and 71.3% in Q1 FY26.

    • ROCE stood at approximately 25% at the end of Q2 FY26.

    • Achieved a S&P Global ESG score of 91 in 2025, a 15-point improvement over 2024.

    Concerns

    3
    • Overall margins in H2 FY26 are expected to be tempered by higher R&D spends and a lower PLI income.

    • Anticipate some erosion in Tolvaptan revenue in the second half of FY26 due to expected competition.

    • The biosimilars portfolio currently has a negative 'burn', though not described as 'hugely negative'.

    What Changed2

    vs Q3 FY26

    Guidance items9 → 14 (+5)Risks discussed3 → 5 (+2)

    Key financials

    Single quarter

    12 metrics
    1. 01Revenue from Operations₹7,048 Cr+24%YoY
    2. 02EBITDA₹2,138 Cr+63%YoY
    3. 03EBITDA Margin31.3%+7.5%YoY
    4. 04Gross Margins73.3%+4%YoY
    5. 05R&D Spend₹509 Cr

    Segment breakdown

    US Business
    315 Mn Revenue
    India
    3.4% Revenue Growth8.8% Core Prescription Business Growth10.7% Normalized Domestic Growth (H1)
    Other Developed Markets
    ₹812 Cr Revenue26.8% Europe Growth (Q2FY26)
    Emerging Markets
    45% Revenue Growth141% Brazil Growth (local currency)
    GIB Business
    9% Revenue Growth
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    USD 250 million

    M&A

    VISUfarma

    acquisition · announced

    Liquidity

    Cash ₹1,665 crores

    Net cash increased from INR 310 crores on March 31, 2025, to INR 1,665 crores as of September 30, 2025.

    Guidance & targets

    13
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    25% to 26%
    High
    Profitability
    EBITDA Margin
    24% to 25%
    High
    R&D
    R&D Spend as % of Sales
    7.5% to 8.5%
    High
    Taxation
    Effective Tax Rate (ETR)
    21% to 22%
    High
    Revenue
    US Business Revenue
    over USD 1 billion
    High
    Product Mix
    Share of Complex Products in US Business
    double
    Medium
    Market Share
    India Formulations Outperformance vs IPM
    1.2 to 1.3 times
    High
    Product Pipeline
    Biosimilars in US Market
    at least five products
    High
    Product Launch Timeline
    Pegfilgrastim Launch
    next couple of weeks (end of November)
    High
    Product Launch Timeline
    Ranibizumab Launch
    middle of next year
    High
    Product Launch Timeline
    Eylea® Launch
    fiscal year '28 or early FY29
    High
    Product Launch Timeline
    Etanercept Launch
    within five-year timeframe
    High
    Revenue Growth
    Europe Growth Rate
    20% plus every year
    Medium

    Tolvaptan Revenue Trajectory

    next quarter (H2 FY26)
    CurrentUSD 315 million in Q2 FY26
    TargetUSD 275-300 million per quarter

    Why it matters

    Tolvaptan is a key revenue contributor in the US, and its performance post-exclusivity will indicate the impact of new competition.

    So, as we look at the next couple of quarters, the second half, we certainly think that we'll have some erosion from this USD 315 million, but we should be, close to between USD 275 million to USD 300 million per quarter to close over USD 1 billion as we have guided in the past.

    How to verify

    key_financials.segment_breakdown[name='US Business'].metrics[label='Revenue']

    Risks & concerns

    5
    RiskSeverity

    Tolvaptan competition post-exclusivity

    180-day exclusivity for Tolvaptan is ending, and some competition is expected, which may lead to revenue erosion in H2 FY26.Management acknowledged

    medium

    Albuterol competition

    While Albuterol has stabilized, Amneal is likely to enter the market, which could cause further erosion.Management acknowledged

    medium

    Spiriva Medicare access challenges

    The company has struggled to gain good access on the Medicare front for Spiriva, despite government focus on biosimilars and generics.Management acknowledged

    medium

    H2 FY26 margin tempering

    Overall margins in H2 FY26 are expected to be tempered by higher R&D spends and a lower PLI income.Management acknowledged

    low

    Nagpur Unit 2 OAI status

    The company is actively addressing the Official Action Indicated (OAI) status at its Pithampur Unit 2 facility.Management acknowledged

    medium

    Q&A highlights

    8

    “So, as we look at the next couple of quarters, the second half, we certainly think that we'll have some erosion from this USD 315 million, but we should be, close to between USD 275 million to USD 300 million per quarter to close over USD 1 billion as we have guided in the past. And then in terms of new launches, just recently we launched the authorized generic to Ravicti®, which is a material launch for us. We are about to launch the Risperdal Consta® product in the next couple of weeks. We have an upcoming goal date for Pegfilgrastim, for which we had a recent inspection at the biotech facility. Feel pretty good about that, so that should be coming up. Victoza® was just launched, so we'll see the ramp up of that. So, injectables certainly, Ravicti® plus biosimilars into the next couple of quarters, and then Ranibizumab next year, we feel pretty good about sustaining a USD 1 billion plus level into fiscal year '27.”

    Provides specific revenue expectations for a key US product (Tolvaptan) and outlines the pipeline of new launches expected to contribute to US revenue in the near future.

    asked by Kunal Dhamesha

    3 min read6 chapters

    Detailed Narrative

    01

    Record Q2 FY26 Performance and Margin Expansion

    Lupin achieved a record Q2 FY26, with total revenue from operations exceeding INR 7,000 crores and EBITDA surpassing INR 2,100 crores for the first time in its history. This robust performance was driven by broad-based growth across all key markets. The company's EBITDA margin expanded significantly to 31.3%, marking an increase of 750 basis points YoY and 470 basis points QoQ, primarily attributed to a favorable product mix, lower share of in-licensed products, and improved operational efficiencies.

    02

    Strong US Business Growth and Complex Product Pipeline

    The US business delivered one of its highest revenue figures to date, reaching USD 315 million, reflecting a 41% YoY and 11.5% QoQ growth. This was bolstered by new product launches such as Tolvaptan, where Lupin continues to enjoy first-to-file exclusivity, and Mirabegron. The company also secured successful approvals for several complex injectables, including generic Victoza and Risperdal long-acting injectable, and aims to double the share of complex products in its US business over the next few years.

    03

    India Formulations Outperformance and R&D Focus

    India revenues grew 3.4% YoY, with the core domestic formulations business delivering a healthy 8.8% growth, outperforming the IPM growth by 1.2 times. When normalized for the impact of loss of exclusivity on certain products, domestic growth stood at a robust 10.7% YoY for H1. R&D spend for the quarter was INR 509 crores, representing 7.5% of sales, with approximately 70% directed towards complex and specialty platforms. The company plans over 80 new product launches, including GLP-1s like Semaglutide, in the coming years.

    04

    Strategic Expansion in Europe and Emerging Markets

    Other Developed markets, including Europe, Canada, and Australia, collectively delivered 19% YoY growth, with Europe being a standout performer, growing 26.8% YoY for Q2 FY26. The planned acquisition of VISUfarma, expected to close by 2025, is set to expand Lupin's European footprint and build a global specialty franchise, aiming for USD 150 million in annualized revenues next year. Emerging markets also demonstrated impressive growth of 45% YoY, significantly led by Brazil's 141% growth in local currency.

    05

    Commitment to Compliance and ESG Leadership

    Lupin received VAI (Voluntary Action Indicated) status for its Pithampur Unit 3 respiratory facility and is actively addressing the OAI (Official Action Indicated) at Unit 2, underscoring its commitment to maintaining the highest global quality and regulatory standards. On the ESG front, the company achieved a remarkable S&P Global ESG score of 91 in 2025, a 15-point improvement over 2024. This achievement positions Lupin as a leader in the pharmaceutical industry for sustainability and responsible growth.

    06

    Capital Investments for Future Growth and Biosimilars Pipeline

    The company announced planned investments of USD 250 million in the US, combining Capex and pipeline, for its Coral Springs site. This investment is aimed at catering to anticipated demand for respiratory products, including the Respimat and Ellipta franchises, and establishing an MDI line. Lupin is also making significant progress on its biosimilars portfolio, with Pegfilgrastim expected to launch in the next few weeks and Ranibizumab in the middle of next year, targeting at least five products in the US market by FY30.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.